Antibody Drug Conjugates and Bi-Specific T cell engagers
Tristar has RNA or IHC data for many of the tumor or immune cell related proteins targeted in Antibody Drug Conjugates and Bi-specific T cell engagers.
Harnessing the Power of Tumor-Targeting Antibodies
Antibodies that bind tumor-expressed proteins are proving to be useful in designing targeted therapeutics. Antibodies can be conjugated with small molecule cytotoxic payloads to make antibody drug conjugates (ADCs) that deliver those payloads to kill tumor cells. Antibodies that enhance the immune system through the blockade of key checkpoint inhibitor proteins, such as the PD1/PD-L1/PD-L2 axis, or by binding and recruiting T cells, can activate the immune system to kill tumor cells.
Breast and Lung cancer are key diseases for ADC therapeutics, with several approved in both diseases, which histological and molecular subtypes express these targets uniquely or competitively and at what levels may be key to future clinical development.
Upgrade your IHC Assay Analysis Today for the Cancer Treatments of Tomorrow
TriStar has optimized IHC assays for PD-L1, HER2 (4B5 & HercepTest), TROP2, NECTIN-4, and B7-H3 that were run on serial slides from tissue microarrays with Standard of Care clinical outcomes data for breast cancer (hormone receptor-positive and triple-negative) and lung cancer (adenocarcinoma and squamous subtypes).
Pathologist scores for each ADC target and Leica/Aperio whole slide images from H&E and IHC stained slides are available. The data may inform where these ADC targets are highest expressed, where they overlap with respect to each other, how expression correlates to SOC outcomes, and their potential for combining with immunotherapies.
TriStar can expand the current results to include additional IHC assays (CLDN 18.2, FOL(a), B7H4, Mesothelin) and disease indications (Gastric ADC, Ovarian cancer, HCC, Prostate ADC, CRC & Pancreatic ADC) either on TMAs or matched whole tissues.
Benefits of choosing Tristar’s services
Tristar multi-tumor or single disease TMAs for most solid tumor and heme malignancies. Normal tissue controls on each TMA or normal tissue TMAs can be used to help establish tumor specific expression of targets.
IHC assays can be developed and used to screen TMAs to establish where a target is expressed and help select tumor types for clinical trials.